- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04067414
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
A Single Cohort, Open-label, Multicenter, Dose-escalation Study of Safety and Efficacy of BZ019 for Adult CD19 Positive Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multicenter, phase 1 study to determine the safety and antitumor activity of BZ019 in adult patients with R/R large B cell lymphoma (DLBCL),including: DLBCL, not otherwise specified (NOS), transformed DLBCL, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements and primary mediastinal B-cell lymphoma (PMBCL).The safety and efficacy of a single dose of different target doses of BZ019 will be evaluated in the dose-escalation phase and dose-expansion phase.
Upon enrollment, subjects will undergo leukapheresis to enable BZ019 product generation. A baseline tumor biopsy (in subjects with accessible disease) and bone marrow aspirate and biopsy will be obtained.
Upon successful BZ019 product generation, subjects will enter the treatment phase and receive BZ019 infusion. A completed treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 infusion. BZ019 will be administered 2 to 14 days after the completion of lymphodepleting chemotherapy.
After the infusion of BZ019, subjects will be in the follow-up period upon 12 months for evaluation the safety and efficacy of BZ019. Subjects will be followed for long-term safety, overall survival even after disease progression.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Tianjin, China, 300020
- Institute of Hematology & Blood Diseases Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent must be obtained prior to any screening procedures
Age ≥ 18 years subjects with Relapsed or refractory large B-cell lymphoma, including: DLBCL,NOS, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, transformed B-cell lymphoma, primary mediastinal B-cell lymphoma (PMBCL).
No response for the last chemotherapy:
- Progressive disease after the last chemotherapy or
- Stable disease after the last chemotherapy, and the maintenance time for stable disease was no longer than 6 month after last dose.
Either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT
- Refractory disease after ASCT or relapsed disease within 12 months after last ASCT (histologically confirmed) or
- No response or relapsed disease for the last therapy after ASCT.
Subjects must be accepted adequate treatment, including at least:
- Treated by CD20 monoclonal antibody (Rituximab) except for CD20 negative.
- Chemotherapy including anthracycline
- Measurable disease at time of enrollment according to the revised international working group response criteria for malignant lymphoma.
- Life expectancy ≥12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status that is either 0 or 1 at screening.
Adequate organ function:
Renal function defined as:
- A serum creatinine of ≤1.5 x Upper Limit of Normal(ULN) or
- Estimated Glomerular Filtration Rate (eGFR) ≥ 60 mL/min/1.73 m2
Liver function defined as:
- Alanine Aminotransferase (ALT) ≤ 5 times the ULN for age
- Bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert-Meulengracht syndrome; patients with Gilbert-Meulengracht syndrome may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN
- Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation > 91% on room air
- Hemodynamically stable and Left Ventricle Ejection Fraction (LVEF) ≥ 45% confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA)
Adequate bone marrow reserve without transfusions defined as:
- Absolute neutrophil count (ANC) > 1000/μL
- Absolute lymphocyte count (ALC) ≥ 300/μL
- Platelets ≥ 50000/μL
- Hemoglobin > 8.0 g/dl
- Must have an apheresis product of non-mobilized cells accepted for manufacturing.
The following medications are excluded:
- Steroids: Therapeutic doses of steroids must be stopped > 72 hours prior to BZ019 infusion. However, the following physiological replacement doses of steroids are allowed: < 6 - 12 mg/m2/day hydrocortisone or equivalent
- Immunosuppression: Any immunosuppressive medication must be stopped ≥ 4 weeks prior to enrollment
- Antiproliferative therapies other than lymphodepleting chemotherapy within two weeks of infusion
- Antibody use including anti-CD20 therapy within 4 weeks prior to infusion or 5 half-lives of the respected antibody, whichever is longer
- CNS disease prophylaxis must be stopped > 1 week prior to BZ019 infusion (e.g. intrathecal methotrexate)
- Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants must agree to use highly effective methods of contraception for at least 12 months following BZ019 infusion and until CAR T cells are no longer present by PCR on two consecutive tests
Exclusion Criteria:
- Prior treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy
- Treatment with any prior gene therapy product, include CAR-T cell therapy.
- Active Central Nervous System (CNS) involvement by malignancy or secondary CNS involvement
- History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or self-immune disease with CNS involvement.
- Prior allogeneic HSCT
- Eligible for and consenting to ASCT
- Chemotherapy other than lymphodepleting chemotherapy within 2 weeks of infusion
- Investigational medicinal product within the last 30 days prior to screening
- Prior radiation therapy within 2 weeks of infusion
- Active replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive )
- HIV positive patients
- Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion)
- Unstable angina and/or myocardial infarction within 6 months prior to screening
Previous or concurrent malignancy with the following exceptions:
- Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)
- In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to the study
- A primary malignancy which has been completely resected and in complete remission for ≥ 5 years
- Pregnant or nursing (lactating) women
- Cardiac arrhythmia not controlled with medical management
- Patients on oral anticoagulation therapy within 1 week prior to BZ019 infusion.
- Prior treatment with any adoptive T cell therapy
- Patients with active neurological auto immune or inflammatory disorders(e.g. Guillain Barre Syndrome, Amyotrophic Lateral Sclerosis)
- Other protocol-related inclusion/exclusion may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BZ019 treatment
Subjects will receive lymphodepleting chemotherapy of fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 infusion.
A 3×3 dose escalation design of BZ019 will be adopted.
|
Subjects will be enrolled in three dose-groups: Dose 1: 1×10^6/kg CAR+ cells; Dose 2: 3×10^6/kg CAR+ cells; Dose 3: 6×10^6/kg CAR+ cells. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: up to 1 year after BZ019 infusion.
|
Number of BZ019 therapy associated adverse events, such as cytokine release syndrome(CRS), chimeric antigen receptor (CAR)-T cell related encephalopathy syndrome(CRES) or other adverse events.
|
up to 1 year after BZ019 infusion.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proliferation of BZ019 in vivo
Time Frame: up to 1 year after BZ019 infusion.
|
measured by PCR
|
up to 1 year after BZ019 infusion.
|
Overall response rate
Time Frame: up to 1 year after BZ019 infusion.
|
CR+PR
|
up to 1 year after BZ019 infusion.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lugui Qiu, MD, Institute of Hematology & Blood Diseases Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QT2018002-EC-4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B Cell Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on BZ019
-
Shanghai Mengchao Cancer HospitalShanghai Cell Therapy Group Co.,LtdRecruiting
-
Shanghai Cell Therapy Group Co.,LtdInstitute of Hematology & Blood Diseases Hospital; Tianjin Medical University...Unknown